-
Mashup Score: 80Home - 29 day(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93Support Toni Choueiri, MD and Robert Haddad, MD - Pickleball for a Purpose Presented by EchoStor Technologies - 1 month(s) ago
I’m excited to join this incredible initiative! This organization’s mission is very important to me and I’m proud to help them make a difference. Please support me by giving to my page. Every dollar counts! Thank you.
Source: charity.pledgeit.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93Support Toni Choueiri, MD and Robert Haddad, MD - Pickleball for a Purpose Presented by EchoStor Technologies - 1 month(s) ago
I’m excited to join this incredible initiative! This organization’s mission is very important to me and I’m proud to help them make a difference. Please support me by giving to my page. Every dollar counts! Thank you.
Source: charity.pledgeit.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
The 3rd transatlantic exchanges between @DanaFarber and @GustaveRoussy happening April 12 in @CityOfBoston —come join us in person or virtually ! Topic: liquid biopsies in Cancer! @LGlimcherMD @barlesi @FAndreMD #Fizazi @OncoAlert logy https://t.co/5mHqMXghMd https://t.co/jsz6kkPQnS